Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.

Yau C, Wang Y, Zhang Y, Foekens JA, Benz CC.

Breast Cancer Res Treat. 2011 Apr;126(3):803-10. doi: 10.1007/s10549-011-1345-1. Epub 2011 Jan 12.


FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.

Yau C, Meyer L, Benz S, Vaske C, Scott G, Egan B, Labhart P, Pourmand N, Benz CC.

Breast Cancer Res Treat. 2015 Nov;154(1):23-32. doi: 10.1007/s10549-015-3589-7. Epub 2015 Oct 12.


Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.

Bergamaschi A, Christensen BL, Katzenellenbogen BS.

Breast Cancer Res. 2011 Jun 29;13(3):R70. doi: 10.1186/bcr2913.


The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.

Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS.

Breast Cancer Res. 2014 Sep 12;16(5):436. doi: 10.1186/s13058-014-0436-4.


Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC.

Breast Cancer Res Treat. 2011 Sep;129(2):607-16. doi: 10.1007/s10549-011-1564-5. Epub 2011 May 20.


Increased expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen receptor-positive breast cancer.

Ahn H, Sim J, Abdul R, Chung MS, Paik SS, Oh YH, Park CK, Jang K.

J Korean Med Sci. 2015 Apr;30(4):390-7. doi: 10.3346/jkms.2015.30.4.390. Epub 2015 Mar 19.


A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.

Szekely B, Iwamoto T, Szasz AM, Qi Y, Matsuoka J, Symmans WF, Tokes AM, Kulka J, Swanton C, Pusztai L.

Breast Cancer Res Treat. 2013 Apr;138(3):691-8. doi: 10.1007/s10549-013-2475-4. Epub 2013 Mar 17.


Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score.

Ahn SG, Lee HM, Lee HW, Lee SA, Lee SR, Leem SH, Jeong J, Chu IS.

Int J Mol Sci. 2013 Dec 4;14(12):23685-99. doi: 10.3390/ijms141223685.


Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.

Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F.

BMC Cancer. 2008 Nov 21;8:339. doi: 10.1186/1471-2407-8-339.


Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L.

J Clin Oncol. 2010 Oct 1;28(28):4316-23. doi: 10.1200/JCO.2009.27.2419. Epub 2010 Aug 30. Erratum in: J Clin Oncol. 2010 Nov 10;28(32):4868. J Clin Oncol. 2012 Feb 20;30(6):679.


Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O.

Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18.


Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.

Sanders DA, Ross-Innes CS, Beraldi D, Carroll JS, Balasubramanian S.

Genome Biol. 2013 Jan 24;14(1):R6. doi: 10.1186/gb-2013-14-1-r6.


Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.

Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC.

Breast Cancer Res. 2008;10(1):R21. doi: 10.1186/bcr1872. Epub 2008 Feb 29.


Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group.

Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z. Epub 2015 Oct 22.


PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.

Yang J, Wu NN, Huang DJ, Luo YC, Huang JZ, He HY, Lu HL, Song WL.

Tumour Biol. 2017 Jul;39(7):1010428317713492. doi: 10.1177/1010428317713492.


ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer.

Horimoto Y, Hartman J, Millour J, Pollock S, Olmos Y, Ho KK, Coombes RC, Poutanen M, Mäkelä SI, El-Bahrawy M, Speirs V, Lam EW.

Am J Pathol. 2011 Sep;179(3):1148-56. doi: 10.1016/j.ajpath.2011.05.052. Epub 2011 Jul 16.


Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.

Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H.

Int J Cancer. 2014 Oct 15;135(8):1898-910. doi: 10.1002/ijc.28831. Epub 2014 Mar 20.

Supplemental Content

Support Center